scholarly journals Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol

2019 ◽  
Vol 3 (11) ◽  
pp. 1472-1481 ◽  
Author(s):  
Christian Labenz ◽  
Jürgen H. Prochaska ◽  
Yvonne Huber ◽  
Michael Nagel ◽  
Beate K. Straub ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Nonalcoholic Fatty Liver ◽  
Risk Categories

scholarly journals Mean Arterial Pressure Is Related to Incident Nonalcoholic Fatty Liver Disease among the Nonobese Female with Normal Low-Density Lipoprotein Cholesterol Levels: A Large Cohort Study in China

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Shangbo Xu ◽  
Lan Chen ◽  
Danhua Hong ◽  
Lihua Yang ◽  
Xiaozhi Li ◽  
...  
Keyword(s):  
Liver Disease ◽  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Cumulative Incidence ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Nonalcoholic Fatty Liver

Aim. We aimed to demonstrate the independent effect of mean arterial pressure (MAP) on incident nonalcoholic fatty liver disease (NAFLD) among the nonobese Chinese with normal low-density lipoprotein cholesterol (LDL-C) levels. Methods. 16,153 nonobese participants without NAFLD at baseline were enrolled and then assigned to four groups by quartiles of MAP (Q1-Q4). A subgroup analysis by gender was also conducted. Participants were diagnosed with NAFLD by ultrasonography. Results. During a mean follow-up of 2.80 years, the cumulative incidence of NAFLD was 14.37 and the incidence rate was 513.17 per 10,000 person-years. The cumulative incidence of NAFLD for the whole population or gender groups gradually increased with the quartiles of MAP (all P<0.001). In the Q4 of MAP, the cumulative incidence of NAFLD for the whole population, male, and female reached up to 6.22 (5.75-6.70), 6.70 (6.21-7.19), and 5.69 (5.24-6.14), respectively. After adjustment for potential confounders, as compared with Q1, the hazard ratio for NAFLD was 1.328 (1.072-1.647), 1.625 (1.276-2.069), and 1.697 (1.231-2.340) for Q2, Q3, and Q4, respectively. In subgroup analysis, the respective hazard ratio for NAFLD in Q2, Q3, and Q4 of MAP was 1.760 (1.276-2.429), 2.080 (1.433-3.019), and 2.377 (1.452-3.890), compared with female in the Q1 of MAP. But MAP was not associated with incident NAFLD in male. Besides, MAP had a larger area under the receiver-operating characteristic curves than SBP or DBP, with optimal cutoff point of 88 mmHg in male and 89 mmHg in female. Conclusions. MAP is an independent predictor for incident NAFLD among nonobese female with normal LDL levels.

scholarly journals Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease

2016 ◽  
Vol 36 (8) ◽  
pp. 1213-1220 ◽  
Author(s):  
Zhenghui G. Jiang ◽  
Elliot B. Tapper ◽  
Margery A. Connelly ◽  
Carolina F. M. G. Pimentel ◽  
Linda Feldbrügge ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Nonalcoholic Fatty Liver

scholarly journals Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Janet Lo ◽  
Michael T. Lu ◽  
Elli A. Kim ◽  
Eric Nou ◽  
Travis R. Hallett ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Double Blind Trial ◽  
Low Density Lipoprotein Cholesterol ◽  
Double Blind ◽  
Nonalcoholic Fatty Liver ◽  
Immunodeficiency Virus

Abstract Hepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatosis. This reduction in hepatosteatosis is associated with reduction in low-density lipoprotein cholesterol with statin therapy.

Sign in / Sign up

Export Citation Format

Share Document